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Summary: Purpose: Valproate (VPA) is an extensively used 
drug in the therapy of epilepsies. One of the most frequently 
reported side effects of VPA is hemorrhagic diathesis. Some 
authors emphasized the decreased platelet count as the basis of 
VPA-induced hemorrhagic diathesis, but some reports sug- 
gested that a significant proportion of patients with normal 
platelet count may still have an altered platelet function. The 
mechanism of the VPA-induced platelet dysfunction has not 
yet been elucidated. A determining element of platelet func- 
tions is the arachidonate cascade. Present ex vivo experiments 
were designed to determine whether a relation exists between 
the incidence of hemostasis caused by VPA and the effect of 
this drug on the arachidonate cascade of platelets. 
Methods: Platelets were isolated from patients receiving 
long-term VPA treatment (serum level, 36.04 f 16.12 pg/ml; n 
= 10) or carbamazepine (CBZ) treatment (serum level, 5.24 + 
2.67 yg/ml; n = 10) and were labeled with ['4C]arachidonic 
acid. (CBZ-treated patients were chosen as a control group, 
because CBZ causes blood dyscrasias similar to those elicited 
by VPA, but there has been no report that CBZ induces a 
platelet dysfunction.) The ''C-eicosanoids were separated by 
means of overpressure thin-layer chromatography and deter- 
mined quantitatively by liquid scintillation. 
Results: Even when the mean plasma concentration of the 
drug was low, VPA treatment reduced the activity of the ara- 
chidonate cascade in platelets. VPA effectively inhibited the 
cyclooxygenase pathway and the synthesis of the strong plate- 
let aggregator thromboxane A,. 
Conclusions: Inhibition of the platelet arachidonate cascade 
may contribute to the platelet-function alterations caused by 
VPA. Key Words: Valproate--P1atelets--Thromboxane- 
Prostaglandin-Hemostasis. 
Valproate (VPA) is one of the drugs most extensively 
used in the therapy of generalized epilepsies. The manu- 
facturers' descriptions of VPA emphasize a risk of rare 
but potentially severe hepatic toxicity. Another important 
side effect of VPA administrations is hemorrhagic diath- 
esis. Patients taking VPA have demonstrated alterations 
in hemostasis, including thrombocytopenia (I) ,  a platelet 
dysfunction (2), a decreased fibrinogen plasma level (3), 
and a low von Willebrand factor antigen titer (4), as well 
as clinically significant bleeding (5,6). Several mecha- 
nisms have been proposed to explain these hematologic 
disturbances, including the formation of a platelet anti- 
body (7), a direct platelet membrane effect (8), and bone 
marrow suppression (9). Some authors emphasized the 
decreased platelet count as the basis of VPA therapy- 
induced hemorrhagic diathesis. On the other hand, Gidal 
et al. (2) suggested that a significant number of patients 
treated with VPA who have platelet counts within the 
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normal range may still have an altered platelet function. 
This is relevant because, for example, clinically signifi- 
cant intraoperative bleeding in a child receiving VPA has 
been reported despite a normal platelet count (6). The 
exact mechanism of the VPA-induced platelet dysfunc- 
tion has not yet been elucidated. 
A determining element of the platelet functions is the 
arachidonate (AA) cascade of the platelets. This is initi- 
ated by a receptor-mediated liberation of AA from phos- 
pholipids on the action of phospholipases (10). The free 
AA is metabolized to lipoxygenase products [ 12-hydro- 
peroxy-5,8,10,14-eicosatetraenoic acid (1 2-HPETE) and 
12-hydroxy-5,8,10,14-eicosatetraenoic acid (12-HETE)] 
and also to cyclooxygenase metabolites [thromboxane 
(Tx) A,, prostaglandin (PG) D,, PGE,, and PGF,,]. The 
formation of TxA, is accompanied by the production of 
12-~-hydroxy-5,8,1O-heptadecatrienoic a id (HHT), with 
the concomitant release of malondialdehyde (MDA; 11). 
Quantitatively and functionally, the most important prod- 
uct of the cyclooxygenase metabolites of the thrombo- 
cytes is TxA,, which is a potent proaggregatory sub- 
stance, causing platelet shape change, aggregation, and 
the release of granule contents (12). PGD,, on the other 
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hand, is a potent antagonist that inhibits platelet activa- 
tion through increased cyclic adenosine monophosphate 
(CAMP). PGE, and PGF,, also affect platelet activation, 
although to a much lesser extent that TxA, and PGD, 
( 13). Inhibition of the platelet cyclooxygenase, a beneficial 
effect of nonsteroidal antiinflammatory drugs (NSAIDs) 
in anticoagulant therapy, can lead to an increased bleed- 
ing tendency. The lipoxygenase products have no direct 
effects on platelet activation, but they may modulate the 
AA metabolism via the cyclooxygenase pathway (14). 
Our ex vivo experiment was designed to determine 
whether a relation exists between the incidence of he- 
mostasis disorders caused by VPA and the effect of this 
drug on the AA cascade of the platelets. 
METHODS 
Patients 
Patients were recruited from the Department of Neu- 
rology, Albert Szent-Gyorgyi Medical University of 
Szeged, Hungary. Inclusion criteria for study participa- 
tion included their abstaining from any medication 
known to alter platelet activation, aggregation, and re- 
lease reaction. After giving written informed consent, 10 
young male patients (mean age, 22.90 f 7.25 years) par- 
ticipated in the study. All had been on a stable VPA 
monotherapy regimen (Depakine Chrono: Sanofi Win- 
throp/Chinoin, Budapest, Hungary; or Convulex: Gerot 
Pharmazeutika, Wien, Austria) for 3 120 days before 
evaluation. The mean VPA dosage was 8.38 ? 2.03 mg/ 
kg/day. The mean total plasma VPA concentration was 
36.04 f 16.12 pg/ml. Seizure types included idiopathic 
generalized epilepsy (n = 7) and cryptogenic or symp- 
tomatic partial epilepsy (n = 3). The control group con- 
sisted of 10 male patients (mean age, 31.50 ? 11.41 
years) receiving stable carbamazepine (CBZ) mono- 
therapy (Neurotop R: Gerot Pharmazeutika, Wien, Aus- 
tria; or Tegretol CR: Novartis, Basel, Switzerland), who 
were subject to the same inclusion criteria. The mean 
CBZ dosage was 8.10 f 2.86 mg/kg/day. The mean total 
plasma CBZ concentration was 5.24 ? 2.67 pg/ml. Sei- 
zure types involved cryptogenic or symptomatic partial 
epilepsy (n = 10). CBZ-treated patients were chosen as 
control group because CBZ causes blood dyscrasias (leu- 
kopenia and thrombocytopenia) similar to those elicited 
by VPA ( 1  3, but there has been no report of CBZ in- 
ducing a platelet dysfunction. Investigations were per- 
formed with the permission and approval of the Human 
Investigation. Review Board of Albert Szent-Gyorgyi 
Medical University, Szeged, Hungary. 
Study design 
Patients and controls were scheduled to report to the 
clinical laboratory between 8 a.m. and 10 a.m. after an 
overnight fast to minimize the impact of fluctuations in 
plasma free fatty acids on the plasma concentrations of 
the drugs. 
Analytic methods 
Cell counting (red blood cells, white blood cells, and 
platelets) and other hematologic parameters [mean cor- 
puscular hemoglobin (MCH), mean corpuscular hemo- 
globin concentration (MCHC), and mean corpuscular 
volume (MCV)] were measured with a Sysmex CC780 
instrument (Medical Electronics Ltd., Kobe, Japan). The 
Ivy bleeding-time test was performed on the forearm. 
The coagulation time was determined by the Burker 
method. The plasma fibrinogen level was determined 
with the Fibri-Prest reagent on an Amelung Coagulom- 
eter KCI A (Diagnostica-Stago, Asnieres, France). Se- 
rum aspartate aminotransferase (ASAT), alanine amino- 
tranferase (ALAT), alkaline phosphatase (ALP), and 
y-glutamyl-transpeptidase (GGT) levels were assayed 
with a Hitachi 917E clinical chemistry analyzer (Boe- 
hringer Mannheim, Mannheim, Germany). Plasma con- 
centrations of VPA and CBZ were determined by fluo- 
rescence polarization immunoassay technology on a TDX 
Analyzer (Abbott Laboratories, Chicago, IL, U.S.A.). 
Study of the platelet AA cascade 
Platelets were isolated from venous blood samples by 
differential centrifugation, as described previously (1 6). 
From the platelets of each patient, two incubation 
samples were prepared. Each incubation mixture con- 
tained lo* cells in 1 ml buffered Medium 199. All 
samples preincubated at 37°C for 5 min and then incu- 
bated with the tracer substrate, L-[ '~C]AA (0.172 pmol, 
3.7 kBq). Ten minutes later, the enzyme reaction was 
stopped by bringing the pH of the incubation mixture to 
3 with formic acid. The ''C-eicosanoids were separated 
by means of overpressure thin-layer chromatography and 
determined quantitatively by liquid scintillation, as de- 
scribed previously (16). 
Data analysis 
Statistical comparisons were made by unpaired t test. 
Associations were measured with the Pearson r correla- 
tion coefficient. 
RESULTS 
AA cascade of platelets 
The platelets of the VPA-treated patients synthesized 
less 12-HETE than did those of the CBZ-treated patients. 
This difference (p = 0.06) was close to the significance 
level. The platelet cyclooxygenase activity in the VPA- 
treated patients was significantly decreased (p = 0.014). 
The total metabolite formation in the AA cascade of the 
platelets of the VPA-treated patients was decreased sig- 
nificantly (p = 0.018) relative to that of the CBZ-treated 
patients. The main cyclooxygenase metabolite of the 
platelets is TxA,. The synthesis of TxA, (the stable me- 
tabolite of which, TxB,, was determined) was signifi- 
cantly decreased (p = 0.038) in the platelets of the VPA- 
treated subjects. The synthesis of TxA, is accompanied 
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by the parallel production of HHT directly from PGH, 
with the release of MDA. The synthesis of HHT was also 
decreased, and this difference (p = 0.055) was close to 
the significance level. The syntheses of other cyclooxy- 
genase metabolites (PGF,,, PGD,, and PGE,) were like- 
wise decreased in the platelets of the VPA-treated pa- 
tients, but only that of PGD, was decreased significantly 
(p = 0.003; Table I ) .  
Other laboratory examinations 
The analysis of liver enzymes, ASAT, ALAT, ALP, 
and GGT, did not reveal significant differences between 
the VPA-treated and the CBZ-treated patients; with the 
exception of GGT, the values were in the physiological 
range. The serum GGT level was significantly higher 
(p = 0.004) in the CBZ-treated patients compared with 
the VPA-treated patients, and slightly above the upper 
limit of the normal range. The numbers of the corpuscu- 
lar elements of the blood (platelets, white blood cells, 
and red blood cells), the parameters of the red blood cells 
(MCH, MCHC, and MCV) and the hemostatic param- 
eters (plasma level of fibrinogen, bleeding time, and co- 
agulation time) were in the physiological ranges, and 
there was no significant difference between the two pa- 
tient groups (Table 2). 
Interpatient correlations 
No statistically significant correlations were found be- 
tween the Tx production of the platelets and the plasma 
VPA concentrations (Y = 0.402), the daily dose of VPA 
( r  = 0.002), or the duration of VPA treatment ( Y  = 0.3). 
DISCUSSION 
VPA is an effective, widely used AED, but there have 
been a number of reports that VPA treatment causes 
alterations in hemostasis, and it is believed by some re- 
searchers to increase surgical bleeding (5,6). The most 
frequently noted cause of these hemostatic abnormalities 
is thrombocytopenia. Additionally, VPA treatment is 
known to cause a platelet dysfunction (2). One of the 
most important elements in the regulation of the platelet 
functions is the AA cascade of the platelets. 
Our data demonstrate that, even when the mean 
plasma concentration of the drug was low (36.04 + 16.12 
pg/ml), it was less than the usual therapeutic range, but 
the patients were seizure free according to the clinical 
symptoms and EEG signs, the applied VPA treatment 
reduced the activity of the AA cascade in the platelets. 
VPA inhibited the cyclooxygense pathway more effec- 
tively than the lipoxygenase pathway. 
The hematologic parameters and the serum liver en- 
zyme levels of the patients were in the physiological 
range. A higher therapeutic dose of VPA might alter 
these results. 
TxA, is functionally the most important product of the 
platelet AA cascade, and its synthesis was inhibited by 
VPA. The Tx synthesis of the platelets is accompanied 
by the parallel production of HHT and MDA ( 1  I ) .  Our 
results are in agreement with the findings of Voss et al. 
(17), who demonstrated a decreased MDA production i n  
patients receiving VPA therapy. 
Different types of platelet-activator substances (colla- 
gen, ADP, thrombin, AA, and ristocetin) are used to test 
the platelet function. Thrombin induces an AA cascade- 
independent, whereas AA elicits an AA cascade- 
dependent platelet activation and aggregation (1 8). Gidal 
et al. (2) reported a decreased AA-induced platelet acti- 
vation (the platelet ATP release was measured) and ag- 
gregation in VPA-treated subjects, but they did not ob- 
serve differences in thrombin-induced platelet activation 
as compared with their control group. The results of 
Gidal et al. (2) demonstrated that the VPA-induced plate- 
let dysfunctions involve alterations in the AA cascade. 
We found a lower activity of the AA cascade and a 
decreased production of TxA, in the platelets of patients 
receiving VPA therapy, which lends support to the find- 
ings of Gidal et al. (2). 
In contrast with Gidal et al. (2), who reported dose- 
related effects of VPA on the platelet functions. we did 
not find correlations between the Tx synthesis of the 
platelets and the plasma concentration or the applied 
dose of VPA, which may suggest idiosyncratic action of 
the drugs, although it is possible that the reason for the 
lack of an apparent concentration-effect relation could 
be the low mean VPA plasma concentrations. 
The mechanism of action of VPA on the platelet AA 
cascade has not yet been elucidated. VPA may possibly 
cause alterations in the membrane phospholipids of the 
platelets, as in the erythrocytes (8), or reduce the calcium 
TABLE 1. Effects of vulproute treatment on the arachidonute cascade of platelets 
PGFZ, PGE, PGD, HHT TxB, co LO Total 
_ _  ___-. - - - 
Control 2.7 I 5  f 22 I 3.347 f 208 7,864 f 368 8,723 f 874 3 1,763 f 2,275 54,4 12 f 3,283 I 6  1,392 f 4,203 2 15,804 f 6,65 I 
VPA 2,2 18 f 143 2,929 f I 5  1 5,624" f 543 6,555 f 597 24.942" f 2.026 42,268" f 2.970 138.885 + 10,403 181,154" f I 1,559 
Each value represents the mean ? standard errors of radioactive arachidonate metabolites in dpm. 
Control. group of patients receiving stable carbamazepine monotherapy (n = 10); VPA, group of patients receiving stable valproate monotherapy 
(n = 10): PG, prostaglandin: HHT, I2-~-hydroxy-5,8,I0-heptadecatrienoic a id: TxB,, thromboxane B,; CO, cyclooxygenase metabolites; LO, 
lipoxygenase metabolites; Total, sum of arachidonate metabolites (Total = CO + LO). 
" p < 0.05. compared with the control. 
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TABLE 2. Effects of valproate treatment on liver en7ymes and hematologic paramters 
Control VPA Normal range 
ASAT (U/L) 
ALAT ( U L )  
ALP (U/L) 
GOT (U/L) 
Fibrinogen (mg/dl) 
Coagulation time (min) 
Ivy bleeding time (min) 
Platelet count (10'/1~.1) 
WBC count (1  0'/1~.l) 
RBC count ( I  0'/1~.l) 
MCH (pg/cell) 
MCHC (g/dl) 
MCV (fl/cell) 
22.80 5 3.46 
24.00t 3.58 
2 13.40 c 22.77 
54.50% 9.27 
308.30 t 34.05 
6.25 c 0.38 
5.47 t 0.62 
2925 29 
5.34t 0.59 
4.91 c 0.07 
31.03 f 0.38 
31.87 t 0.49 
97.90c 1.32 
22.90k 1.31 
21.605 3.47 
190.30 t 24.51 
21.20c 4.14' 
279.30 f 19.61 
6.01 t 0.36 
4.86 f 0.55 
2432 28 
5.97 f 0.59 
4.97 5 0.07 
31.42 f 0.49 
32.03 5 0.34 
98 . l0 t  1.41 
<37 
<40 
<270 
I 1-50 
200-450 
5-8 
3-7 
I50450 
3.4-10 
2.4-5.6 
26-34 
31-36 
80- 100 
The tabulated data are expressed as mean values * standard errors. 
Control, group of patients receiving stable carbamazepine monotherapy (n = 10); VPA, group of 
patients receiving stable valproate monotherapy (n = 10); Normal range, physiological range of 
parameters in our laboratory; ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase; 
ALP, alkaline phosphatase; GGT, y-glutamyl-transpeptidase; WBC. white blood cells; RBC, red 
blood cells; MCH, mean corpuscular hemoglobin; MCHC. mean corpuscular hemoglobin concen- 
tration; MCV, mean corpuscular volume. 
p < 0.05, compared with the control. 
current in the platelets, as in the neurons ( I  9), modifying 
the intracellular calcium level, which plays an important 
role in the activation of the AA cascade of the platelets. 
However, Kusumi et al. (20) reported that VPA did not 
alter the calcium concentration in the platelets. 
There is a controversy as to whether VPA induces an 
increased bleeding tendency (5,6,2 1). Our data revealed 
that a low dose of VPA inhibits the Tx production of the 
platelets, which may lead to decreased platelet activation 
and aggregation. Our results draw attention to the pos- 
sibility of the administration to patients with VPA 
therapy of other drugs with inhibitory effects on the 
platelet function, thereby increasing the risk of bleeding. 
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